Journal Article (Letter)

DKFZ-2024-01192

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemia.

Schlenk, R. (Last author)DKFZ*

2024
Ferrata Storti Foundation Pavia

This record in other databases:  

Please use a persistent id in citations: doi:10.3324/haematol.2024.285624

Keyword(s): Humans (MeSH) ; Cytarabine: therapeutic use (MeSH) ; Cytarabine: administration & dosage (MeSH) ; Leukemia, Myeloid, Acute: genetics (MeSH) ; Leukemia, Myeloid, Acute: drug therapy (MeSH) ; Consolidation Chemotherapy (MeSH) ; Male (MeSH) ; Female (MeSH) ; Middle Aged (MeSH) ; Antimetabolites, Antineoplastic: therapeutic use (MeSH) ; Antimetabolites, Antineoplastic: administration & dosage (MeSH) ; Prognosis (MeSH) ; Adult (MeSH) ; Aged (MeSH) ; Biomarkers, Tumor: genetics (MeSH) ; Treatment Outcome (MeSH) ; Cytarabine ; Antimetabolites, Antineoplastic ; Biomarkers, Tumor

Note: #LA:W010# / Haematologica | LANDMARK PAPER IN HEMATOLOGY

---

Contributing Institute(s):

1. Klinische Studienzentrale (W010)

Research Program(s):

1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2024

---

Database coverage:
; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---